Detecting and Treating HER2 Alterations in Metastatic Colorectal Cancer: Expert and Patient Perspectives - Episode 5

Barriers to Molecular Testing in Metastatic Colorectal Cancer

, ,

Tanios Bekaii-Saab, MD, explains the barriers to molecular testing for patients with metastatic colorectal cancer, and how they can be addressed.

EP. 1: An Overview of Metastatic Colorectal Cancer (mCRC)
EP. 2: A Patient’s Diagnosis with HER2+ Metastatic Colorectal Cancer
EP. 3: The Importance of Molecular Testing in Metastatic Colorectal Cancer
EP. 4: Explaining Molecular Testing to Patients with Metastatic Colorectal Cancer
Now Viewing
EP. 5: Barriers to Molecular Testing in Metastatic Colorectal Cancer
EP. 6: First-Line Treatment Options for HER2+ Metastatic Colorectal Cancer
EP. 7: A Patient’s Treatment Journey with HER2+ Metastatic Colorectal Cancer
EP. 8: Appropriate Patient Selection for Patients with HER2+ Metastatic Colorectal Cancer for Anti-HER2 Therapies
EP. 9: Toxicity Management with Trastuzumab Deruxtecan in HER2+ Metastatic Colorectal Cancer
EP. 10: The MOUNTAINEER Trial of Tucatinib for Treatment of HER2+ mCRC
EP. 11: Recap: Discussing Treatment Updates in CRC With a Patient Advocate
EP. 12: Managing Toxicities with Tucatinib in Patients with HER2+ mCRC
EP. 13: Advice on HER2+ Metastatic Colorectal Cancer for Patients and Caregivers
EP. 14: Unmet Needs in Patient Care for Metastatic Colorectal Cancer